Patients to benefit from new era in cancer treatment, as Government slashes red tape to unleash life-saving innovation
Similar Posts
Guidance: Medical devices: legal requirements for specific medical products
Information for manufacturers on the regulations that apply to prosthetic, orthotic and ophthalmic devices.
UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps
As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review.
MHRA approves nogapendekin alfa inbakicept to treat adult patients with non-muscle invasive bladder cancer
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 July 2025, approved nogapendekin alfa inbakicept (Anktiva) for adults with BCG-unresponsive non-muscle invasive bladder cancer, where the disease remains confined to the inner lining of the bladder and may include tumours.
Chikungunya vaccine (IXCHIQ) temporarily paused in people aged 65 and over as precautionary measure
This is a precautionary measure while the MHRA conducts the safety review.
Class 4 Medicines Defect Notification: Ipca Laboratories UK Limited, Various Products, EL(25)A/42
Ipca Laboratories UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the products listed in this notification do not contain all the required safety information.
MHRA scientists contribute to international study on novel oral polio vaccine stability
Study confirms vaccine being used in global efforts to achieve and sustain polio eradication is successfully interrupting polio outbreaks whilst minimising risk of new vaccine-derived outbreaks in Uganda